121 related articles for article (PubMed ID: 34058790)
1. Synergistic effect of toosendanin and regorafenib against cell proliferation and migration by regulating WWOX signaling pathway in hepatocellular carcinoma.
Yang T; Huo J; Xu R; Zhang Y
Phytother Res; 2021 Aug; 35(8):4567-4578. PubMed ID: 34058790
[TBL] [Abstract][Full Text] [Related]
2. WWOX activation by toosendanin suppresses hepatocellular carcinoma metastasis through JAK2/Stat3 and Wnt/β-catenin signaling.
Yang T; Xu R; Huo J; Wang B; Du X; Dai B; Zhu M; Zhan Y; Zhang D; Zhang Y
Cancer Lett; 2021 Aug; 513():50-62. PubMed ID: 34015398
[TBL] [Abstract][Full Text] [Related]
3. Albendazole exerts an anti-hepatocellular carcinoma effect through a WWOX-dependent pathway.
Yang T; Cheng C; Xu R; Huo J; Peng X; Chen Y; Liang Y; Su Z; Zhang Y
Life Sci; 2022 Dec; 310():121086. PubMed ID: 36257459
[TBL] [Abstract][Full Text] [Related]
4. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
[TBL] [Abstract][Full Text] [Related]
5. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
6. Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30).
Yang Q; Guo X; Yang L
Med Sci Monit; 2018 Apr; 24():2225-2234. PubMed ID: 29654226
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1237-1245. PubMed ID: 25907508
[TBL] [Abstract][Full Text] [Related]
8. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway.
Wang J; Zhang N; Han Q; Lu W; Wang L; Yang D; Zheng M; Zhang Z; Liu H; Lee TH; Zhou XZ; Lu KP
Cancer Lett; 2019 Mar; 444():82-93. PubMed ID: 30583078
[TBL] [Abstract][Full Text] [Related]
9. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
Wu LW; Zhou DM; Zhang ZY; Zhang JK; Zhu HJ; Lin NM; Zhang C
Biochem Biophys Res Commun; 2019 May; 512(4):852-858. PubMed ID: 30929918
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression.
Xu J; Huang F; Yao Z; Jia C; Xiong Z; Liang H; Lin N; Deng M
Cell Commun Signal; 2019 Jul; 17(1):85. PubMed ID: 31349793
[TBL] [Abstract][Full Text] [Related]
11. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
Liu S; Du Y; Ma H; Liang Q; Zhu X; Tian J
Cancer Lett; 2019 Jul; 453():74-83. PubMed ID: 30928380
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
13. Evodiamine Exerts an Anti-Hepatocellular Carcinoma Activity through a WWOX-Dependent Pathway.
Hu CY; Wu HT; Su YC; Lin CH; Chang CJ; Wu CL
Molecules; 2017 Jul; 22(7):. PubMed ID: 28708106
[TBL] [Abstract][Full Text] [Related]
14. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
15. The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib.
Zhuo J; Lu D; Lin Z; Yang X; Yang M; Wang J; Tao Y; Wen X; Li H; Lian Z; Cen B; Dong S; Wei X; Xie H; Zheng S; Shen Y; Xu X
Cell Death Dis; 2021 Nov; 12(12):1084. PubMed ID: 34785656
[TBL] [Abstract][Full Text] [Related]
16. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.
Yu CC; Huang SY; Chang SF; Liao KF; Chiu SC
Molecules; 2020 May; 25(10):. PubMed ID: 32466169
[TBL] [Abstract][Full Text] [Related]
17. A long non-coding RNA TSLD8 inhibits hepatocellular carcinoma by stabilizing WWOX.
Xu F; Wang B; Liu M; Liu T; Zhang R
Biochem Biophys Res Commun; 2019 Aug; 516(2):526-532. PubMed ID: 31230746
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice.
Weng MC; Wang MH; Tsai JJ; Kuo YC; Liu YC; Hsu FT; Wang HE
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29535278
[TBL] [Abstract][Full Text] [Related]
19. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
[TBL] [Abstract][Full Text] [Related]
20. The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX.
Aderca I; Moser CD; Veerasamy M; Bani-Hani AH; Bonilla-Guerrero R; Ahmed K; Shire A; Cazanave SC; Montoya DP; Mettler TA; Burgart LJ; Nagorney DM; Thibodeau SN; Cunningham JM; Lai JP; Roberts LR
J Hepatol; 2008 Sep; 49(3):373-83. PubMed ID: 18620777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
